TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00492115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CPAP
Description: Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
Study: NCT00840528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: 0.4 ppm ozone for 2 hours
Study: NCT01706744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate care unit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local health care 1
Study: NCT03831347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 12 weeks of Hatha Yoga
Study: NCT02278588

Intervention type: DRUG
Intervention: Rasagiline
Study: NCT01706744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local health care 2
Study: NCT01440829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Description: The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
Study: NCT02603939

Intervention type: PROCEDURE
Intervention: Joint replacement surgery
Description: We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
Study: NCT02411877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Device: Trevo Pro Retriever (Stryker Corp.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trevo Pro Retriever (Stryker Corp.)
Description: Device: Trevo Pro Retriever (Stryker Corp.)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo Pro Retriever (Stryker Corp.)
Description: Device: Trevo Pro Retriever (Stryker Corp.)
Study: NCT04615663

Intervention type: BEHAVIORAL
Intervention: Score SMI
Description: the investigator will complete the SMI score
Study: NCT04321148

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care PCI
Description: optimal medical care PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impella-protected PCI
Description: Impella-protected PCI
Study: NCT02677987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention systematic light exposure
Description: Bright light using Litebook device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison systematic light exposure
Description: Dim light using modified Litebook device.
Study: NCT02411877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll Thermogard XP technology with the Quattro catheter
Description: Device: Zoll Thermogard XP technology with the Quattro catheter
Study: NCT01318291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCRI Group
Description: Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
Study: NCT01064401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: Daclizumab High Yield Process for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a Placebo
Description: Placebo to interferon beta-1a intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a for intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab High Yield Process Placebo
Description: Placebo to Daclizumab High Yield Process subcutaneous injection
Study: NCT00763308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Heart Healthy Program
Description: The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
Study: NCT02738151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300U/mL
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec, 100 U/mL
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-insulin anti-diabetic treatment
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-insulin anti-diabetic treatment
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Study: NCT04247360

Intervention type: DEVICE
Group type: OTHER
Intervention: cuff pressure
Description: maintaining cuff pressure according the groups
Study: NCT01318291

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Medical treatment alone
Study: NCT02894294

Intervention type: OTHER
Intervention: implementation of seasonal malaria chemoprevention
Description: administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
Study: NCT01112189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compressed sleeve treatment
Description: Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment
Study: NCT04296721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive weigh-loss program
Description: Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary recommendations
Description: Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
Study: NCT00685828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: By mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: By mouth
Study: NCT01296230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hormone and semen measurements before varicocelectomy
Description: Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
Study: NCT02074475

Intervention type: OTHER
Intervention: Control group
Description: A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
Study: NCT01914510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Study: NCT04722692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Delayed SLND
Description: SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Late SLND
Description: SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer.
Study: NCT00537810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: 15 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT + Sibutramine
Description: Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT + Placebo
Description: Cognitive behavioral treatment manual for binge eating Placebo daily
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
Study: NCT02434250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
Study: NCT01913015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive low fat breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive low fat breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive high fat breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive high fat breakfast
Study: NCT03196869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy
Description: Chrono-chemotherapy+concurrent radiochemotherapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip
Description: Routine intravenous drip-chemotherap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction Chrono-chemotherapy
Description: Experimental group:docetaxel,cisplatin,5-FU

Intervention type: DRUG
Group type: OTHER
Intervention: induction Routine-chemotherapy
Description: control group:docetaxel,cisplatin,5-FU
Study: NCT01913015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03310008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Study: NCT01913015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02542566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy rehabilitation
Description: Physiotherapy rehabilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy rehabilitation
Description: Physiotherapy rehabilitation
Study: NCT05008302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
Study: NCT01278810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
Study: NCT03196869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy
Description: Experimental group: cisplatin chrono-chemotherapy
Study: NCT02701569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Repeated jumping on a mini trampoline was administered
Study: NCT02109939

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: GeneSight Psychotropic
Description: The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: GeneSight Psychotropic
Description: The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented.
Study: NCT03823963

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mepilex® Border dressing
Description: Soft silicone self-adherent dressing (5-layers)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The control group will receive pressure ulcer prevention standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The control group will receive pressure ulcer prevention standard care
Study: NCT03441399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Providing money for taking antidepressant medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Providing money for taking antidepressant medication
Study: NCT02237573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written medical report and standardized medical advices
Description: The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator.
Study: NCT05385172

Intervention type: OTHER
Intervention: No any intervation.
Description: This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
Study: NCT04316780

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
Study: NCT03196869

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy
Description: control group:cisplatin routine-chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: control group is similar to Experimental group

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Description: control group is similar to Experimental group
Study: NCT00245635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
Study: NCT04972890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution